Entavir 0.5mg
DESCRIPTION
Entavir 0.5mg is a Cipla product, available in tablet form used to treat hepatitis B viral infection, Entavir 0.5mg containing Entecavir is predominantly used anti-viral agent, which produces better action while compared to previous medicines like lamivudine or Adefovir.
Entecavir expels anti-viral activity against hepatitis B viral infection by involving in inhibiting three steps of viral multiplication process. Entavir 0.5mg is a guanine analogue. Entecavir is majorly used in adolescent patient, and in pediatric with age of 2 years or older.
CAUTION WITH USE OF ENTAVIR 0.5MG
The most severe adverse effects acquiring in the patients after the therapy who are receiving Entecavir, include as Serious worsening of hepatitis B viral infection in HIV/HBV co infected patients. Severe hepatomegaly with steatosis & Lactic acidosis, reported with the use nucleoside analogs or concomitant with other anti-retroviral. There is a possibility of getting resistance to HIV nucleoside reverse transcriptase inhibitors, if Entavir 0.5mg is used in the treatment of chronic hepatitis B infection in HIV patients, not actually treated. Treatment with Entavir 0.5mg tablets should not be recommended for HIV-1/HBV co infected patients, not receiving highly active anti-retroviral therapy.
AVAILABILITY OF STRENGTH OF ENTAVIR 0.5MG
PHARMACOLOGY OF ENTAVIR 0.5MG
Entavir containing Entecavir exhibits its anti-viral activity by prohibiting three steps in viral production; Entavir is an anti-viral medicine, which is guanosine nucleoside analogue effective against HBV infection. Entavir is encounters with natural substrate deoxyguanosine triphosphate. Entavir interfere with three activities of HBV polymerase; 1. Base priming 2. Reverse transcription of negative strand from pregenomic messenger RNA 3. Integration of positive strand of HBV DNA. An Entavir tablet has Entecavir, which is inserting into viral DNA has extreme effect of prohibiting the HBV polymerase activity.
HOW THE BODY WORKING FOR ENTAVIR 0.5MG TABLETS
Entavir 0.5mg tablet, after an oral administration it may undergo ADME properties. The peak plasma concentration time of Entecavir is occurs within 0.5 & 1.5 hours. The steady state of Entecavir is accomplished after 6 to 10 days of single dose administration. Entavir 0.5MG Cmax value is 4.2ng/ml and trough plasma concentration is 0.3ng/ml Entavir 1mg Cmax value is 8.2ng/ml and trough plasma concentration is 0.5ng/ml
EFFECT OF FOOD
Oral administration of Entavir 0.5mg with high fat meal causes decreasing the absorption, depletes Cmax of 44 to 46%, decreases AUC of 18 to 20%.
DISTRIBUTION The volume of distribution is exuberance of total body water; Entecavir is intensively distributed into tissues. The binding of Entecavir with serum proteins occurs relatively 13%. METABOLISM Entecavir should not be considering as cytochrome P450 enzymes substrate, inhibitor or inducers, which is effectively phosphorylated into an active triphosphate form. ELIMINATION Entecavir is eliminated through kidney, in an unchanged form with the range 62% to 73%. The plasma concentration of Entecavir depletes in bi-exponential manner with the mean terminal half life period of relatively 128 to 148 hours.
ENTAVIR 0.5MG MEDICAL BENEFITS
Entavir tablets are used to treat chronic hepatitis B viral infection mostly in adolescent patients with the sign of viral multiplication and other information of enduring elevation of serum aminotransferase or active disease. The important points take into consideration, while starting the therapy with Entavir 0.5mg tablets; Uses of Entavir is based on clinical trial data in nucleoside inhibitor-therapy naïve and lamivudine resistant patients with HBeAg positive and HBeAg negative HBV infection and compensated liver cirrhosis & decompensated cirrhosis. Entavir 0.5mg is used in pediatric patients with 2 years of age or older, with treatment naïve, lamivudine resistant with HBeAg positive HBV infection & compensated liver cirrhosis.
RENAL AND HEPATIC IMPAIRMENT
Depending upon creatinine clearance, the dosage of Entecavir is suggested for patients who are having renal damage. They may follow the dosage adjustments. The safety and effectiveness of Entecavir in hepatic impaired patients has not been evaluated. If Entavir is necessary to take in hepatic impairment patients, who are already receiving Immuno suppressant like cyclosporine, Tacrolimus or sirolimus causes affecting the renal function. Patient must examine periodically before or after the therapy using with Entavir 0.5mg .
OVER DOSAGE
If over dosage of Entecavir occurs, confirmation of toxicity should be taken and provide supportive measures. Following 1mg of Entecavir, nearly 13% of Entecavir dose should be eliminated by hemodialysis method.
MISSED DOSE
Entavir 0.5mg is used in chronic hepatitis B infection, if dose of Entecavir is fail to take by the patients, must consult with medical practitioner and take the dose within a time. On the other hand the missed dose is avoided and follows the regular schedule.
PREGNANCY & LACTATION
The pregnancy category of Entavir tablets is C Entecavir tablets should not be used in pregnancy condition. Entavir used in pregnancy for necessary condition, if risk and benefits are clearly known. In animal clinical studies reveals that Entecavir is excreted in human milk, but human data is not applicable. Breast feeding should be avoided, because most of the drugs are eliminated in human milk. To avoid problems related to Entecavir, it should be taken into consideration.
CONTACT US
PHONE NO: +919940472902
EMAIL: [email protected]
WEBSITE:https://pillsbag.com/products/entavir